Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate

Amneal Pharmaceuticals (AMRX) announced the U.S. Food and Drug Administration, FDA, approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025. “Our Affordable Medicines portfolio continues to grow with a strong and diverse pipeline that supports broader access to high-quality treatments across the U.S. healthcare system,” said Andy Boyer, Executive Vice President and Chief Commercial Officer, Affordable Medicines. “The approval of prednisolone acetate ophthalmic suspension-a complex product to develop and manufacture-highlights the depth of our R&D capabilities and the strength of our manufacturing and supply operations.”